Brian Polonet is the new Vice President of Sales and Marketing at Simplify Medical Pty Ltd, based in Sunnyvale, California.
Brian Polonet: New Vice President at Simplify Medical

According to the company, “Polonet will lead the Company’s sales and marketing initiatives to drive increased adoption in Europe and prepare for expected commercial launch in the U.S. following requisite regulatory approval.”
“Polonet joins the Company with 25 years of experience in the medical device industry, with the last 17 years in Spine. Most recently he was a managing partner at TDR Associates, a consulting company which managed the one and two-level study enrollment for Simplify Medical. He previously held positions as Vice President of Sales and Marketing at Paradigm Surgical, LLC and prior to that, as Vice President of Sales at SpinalMotion. He has had a leadership role in four IDE studies for artificial discs. Polonet holds a Bachelor of Arts in Business Administration from Austin College.”
David Hovda, CEO of Simplify Medical, commented, “I am extremely pleased to announce the high caliber additions of Polonet and Norton to our team as we work diligently to expand our commercial and corporate presence and prepare to bring our innovative disc to the U.S. market following FDA PMA submission and approval. These appointments complement the progress we’ve made to date, especially in the enrollment for our one and two-level IDE clinical trials and demonstrate our evolving focus as we build off our momentum and approach a critical juncture of growth.”
Polonet told OTW, “I am excited to lead the sales and marketing efforts for the next-generation Simplify Disc. I am looking forward to building upon our early European adoption of the Simplify technology as we prepare for the U.S. market.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.